283 related articles for article (PubMed ID: 36428605)
1. Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario.
Krekeler C; Reitnauer L; Bacher U; Khandanpour C; Steger L; Boeckel GR; Klosner J; Tepasse PR; Kemper M; Hennies MT; Mesters R; Stelljes M; Schmitz N; Kerkhoff A; Schliemann C; Mikesch JH; Schmidt N; Lenz G; Bleckmann A; Shumilov E
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428605
[TBL] [Abstract][Full Text] [Related]
2. Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial.
Thakkar A; Pradhan K; Duva B; Carreno JM; Sahu S; Thiruthuvanathan V; Campbell S; Gallego S; Bhagat TD; Rivera J; Choudhary G; Olea R; Sabalza M; Shapiro LC; Lee M; Quinn R; Mantzaris I; Chu E; Will B; Pirofski LA; Krammer F; Verma A; Halmos B
Elife; 2023 Mar; 12():. PubMed ID: 36975207
[TBL] [Abstract][Full Text] [Related]
3. Rituximab-treated rheumatic patients: B cells predict seroconversion after COVID-19 boost or revaccination in initial vaccine non-responders.
Ammitzbøll C; Kragh Thomsen M; Bøgh Andersen J; Jensen JMB; From Hermansen ML; Dahl Johannsen A; Larsen ML; Mistegaard CE; Mikkelsen S; Szabados F; Vils SR; Erikstrup C; Hauge EM; Troldborg A
Rheumatology (Oxford); 2023 Jul; 62(7):2544-2549. PubMed ID: 36445008
[TBL] [Abstract][Full Text] [Related]
4. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
5. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
6. Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination.
Sisteré-Oró M; Wortmann DDJ; Andrade N; Aguilar A; Mayo de Las Casas C; Casabal FG; Torres S; Bona Salinas E; Raventos Soler L; Arcas A; Esparre C; Garcia B; Valarezo J; Rosell R; Güerri-Fernandez R; Gonzalez-Cao M; Meyerhans A
Front Immunol; 2022; 13():908108. PubMed ID: 35911701
[TBL] [Abstract][Full Text] [Related]
7. Effect of Third and Fourth mRNA-Based Booster Vaccinations on SARS-CoV-2 Neutralizing Antibody Titer Formation, Risk Factors for Non-Response, and Outcome after SARS-CoV-2 Omicron Breakthrough Infections in Patients on Chronic Hemodialysis: A Prospective Multicenter Cohort Study.
Tillmann FP; Figiel L; Ricken J; Still H; Korte C; Plaßmann G; Harth A; Jörres A; von Landenberg P
J Clin Med; 2022 Jun; 11(11):. PubMed ID: 35683580
[TBL] [Abstract][Full Text] [Related]
8. [COVID-19 infections and effectiveness of the vaccination among healthcare workers].
Rojkovich B; Németh D; Dinya E; Nagy E; Török E; Lázár I; Perduk A; Géher P; Nagy G
Orv Hetil; 2023 Feb; 164(5):163-171. PubMed ID: 36739547
[TBL] [Abstract][Full Text] [Related]
9. Individuals With Weaker Antibody Responses After Booster Immunization Are Prone to Omicron Breakthrough Infections.
Möhlendick B; Čiučiulkaitė I; Elsner C; Anastasiou OE; Trilling M; Wagner B; Zwanziger D; Jöckel KH; Dittmer U; Siffert W
Front Immunol; 2022; 13():907343. PubMed ID: 35812411
[TBL] [Abstract][Full Text] [Related]
10. Seroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic malignancies.
Ollila TA; Masel RH; Reagan JL; Lu S; Rogers RD; Paiva KJ; Taher R; Burguera-Couce E; Zayac AS; Yakirevich I; Niroula R; Barth P; Olszewski AJ
Cancer; 2022 Sep; 128(18):3319-3329. PubMed ID: 35811461
[TBL] [Abstract][Full Text] [Related]
11. Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents.
Puthanakit T; Nantanee R; Jaru-Ampornpan P; Chantasrisawad N; Sophonphan J; Meepuksom T; Jupimai T; Sodsai P; Anugulruengkitt S; Hirankarn N;
Vaccine X; 2022 Dec; 12():100211. PubMed ID: 36059600
[TBL] [Abstract][Full Text] [Related]
12. Quantitative Analysis of SARS-CoV-2 Antibody Levels in Cancer Patients Post Three Doses of Immunization and Prior to Breakthrough COVID-19 Infections.
Macrae K; Martinez-Cajas J; Bessai K; Abdulhamed A; Gong Y
Curr Oncol; 2022 Sep; 29(10):7059-7071. PubMed ID: 36290831
[TBL] [Abstract][Full Text] [Related]
13. Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment.
Su E; S Fischer ; R Demmer-Steingruber ; Nigg S; Güsewell S; Albrich WC; Rothermundt C; Silzle T; Kahlert CR
ESMO Open; 2022 Oct; 7(5):100587. PubMed ID: 36156449
[TBL] [Abstract][Full Text] [Related]
14. Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications - A pilot study.
Moser T; Otto F; O'Sullivan C; Hitzl W; Pilz G; Harrer A; Trinka E; Wipfler P
Mult Scler Relat Disord; 2022 Mar; 59():103560. PubMed ID: 35093840
[TBL] [Abstract][Full Text] [Related]
15. The Effects of an mRNA Covid-19 Vaccine Booster on Immune Responses in Cancer-Bearing Veterans.
Frankel AE; Capozzola T; Andrabi R; Ahn C; Zhou P; He WT; Burton DR
Med Res Arch; 2022 Jul; 10(7):. PubMed ID: 36405515
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
17. Antibody Response after Homologous and Heterologous Prime-Boost COVID-19 Vaccination in a Bangladeshi Residential University Cohort.
Adnan N; Haq MA; Akter S; Sajal SMSA; Islam MF; Mou TJ; Jamiruddin MR; Jubyda FT; Islam MS; Tuli JF; Liza SM; Hossain S; Islam Z; Ahmed S; Khandker SS; Hossain R; Ahmed MF; Khondoker MU; Azmuda N; Parvez MAK
Vaccines (Basel); 2024 Apr; 12(5):. PubMed ID: 38793733
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Folegatti PM; Ewer KJ; Aley PK; Angus B; Becker S; Belij-Rammerstorfer S; Bellamy D; Bibi S; Bittaye M; Clutterbuck EA; Dold C; Faust SN; Finn A; Flaxman AL; Hallis B; Heath P; Jenkin D; Lazarus R; Makinson R; Minassian AM; Pollock KM; Ramasamy M; Robinson H; Snape M; Tarrant R; Voysey M; Green C; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
Lancet; 2020 Aug; 396(10249):467-478. PubMed ID: 32702298
[TBL] [Abstract][Full Text] [Related]
19. Kinetics of cellular and humoral immunogenicity and effectiveness of SARS-CoV-2 booster vaccination in hematologic neoplasms.
Jiménez M; Fernández-Naval C; Navarro V; Novoa S; Martinez-Gallo M; Medina D; Andrés C; Antón A; Peralta S; Pujadas G; Hernández C; Pagès C; Roldán E; Pumarola T; Gironella M; Ruiz-Camps I; Martínez-Gómez X; Valcárcel D; Hernández M; Bosch F; Crespo M; Esperalba J; Abrisqueta P
Am J Hematol; 2023 Aug; 98(8):1204-1213. PubMed ID: 37151135
[TBL] [Abstract][Full Text] [Related]
20. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.
Peeters M; Verbruggen L; Teuwen L; Vanhoutte G; Vande Kerckhove S; Peeters B; Raats S; Van der Massen I; De Keersmaecker S; Debie Y; Huizing M; Pannus P; Neven K; Ariën KK; Martens GA; Van Den Bulcke M; Roelant E; Desombere I; Anguille S; Goossens M; Vandamme T; van Dam P
ESMO Open; 2021 Oct; 6(5):100274. PubMed ID: 34597941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
